leisure time -WSS

leisure time

author：entertainment 2025-09-14 06:58:24 - browse：8723

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

In an abrupt change of course from plans earlier in the month, at-home test maker Cue Health is laying off all of its employees and shutting down as of Friday, May 24.

The company, which grew to prominence during the Covid-19 pandemic as the maker of one of the only molecular at-home tests for the virus, has been teetering on the edge of insolvency for months. The shutdown, first reported by the San Diego Union-Tribune, comes just over a week after the FDA warned consumers not to use Cue’s only FDA-authorized product, a Covid-19 test kit.

Cue had previously notified 49% of its workers on May 1 that they would be laid off from the company, effective July 1. But in a WARN notice filed with California state regulators on May 20, chief human resources officer Allison Blackwell said that due to the “fluid nature of this situation,” all U.S. employees who had not already received notice of termination would be receiving one. All employees will receive their last paychecks on May 24, the notice said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

WSS

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

With FDA staff opposed to Sarepta therapy, top official intervened

Biogen nominates mother of director’s child to replace him on board

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Cloning humans is technically possible. It's curious no one has tried

A public health expert passes on football's full body collisions for youths

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

In age of alternative facts, a scholarly course on calling out crap

In areas with more Black doctors, Black people live longer

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biogen nominates mother of director’s child to replace him on board

The cancer drug shortage isn’t new — and neither are the solutions

3 hurdles to bringing medical devices to the U.S. market

Sports medicine is finally prioritizing gender equality

The thinking behind the controversial eating disorder chatbot Tessa

Medical leaders decry Supreme Court decision on affirmative action

Eli Lilly’s Mounjaro succeeds in second weight

focus

How to fix the rural physician shortage in the U.S.

Mom launches Girl Scout troop for LGBTQ youth in Texas

STAT's guide to the next generation of CAR

FDA approves first new drug developed for postpartum depression

Inside the rise of 'mukbang' eating videos

With FDA staff opposed to Sarepta therapy, top official intervened

hotspot

knowledge

knowledge

leisure time